Skip to content

CANCER RESEARCH Catalyst

Search for:

Search

Skip to content

Home
About This Blog
Contact Us
Contributors
For the Media
AACR.org

CANCER RESEARCH Catalyst

The Official Blog of the American Association for Cancer Research

B cell FDA approval blog

Posted on January 25, 2017January 25, 2017 by Eileen Glanton Loftus

Share this:

Posted in:

Post navigation

← Ibrutinib Use Expanded to Additional Type of Non-Hodgkin Lymphoma

Leave a Reply Cancel reply

Subscribe via Email

Get the latest blog posts delivered to your inbox.

Email Address

Featured Posts

AACR Annual Meeting 2018: Off-the-shelf CAR T-cell Immunotherapy – Are we There Yet?

AACR Annual Meeting 2018: Novel Immunotherapy Combinations to Combat Resistance to Checkpoint Inhibition

AACR Annual Meeting 2018: A Round-up of Practice-changing Lung Cancer Immunotherapy Clinical Trials

AACR Annual Meeting 2018: Opening Plenary Session on Liquid Biopsy, Immunotherapy, and More

Archives

Archives

Categories

Categories

Subscribe via RSS

RSS - Posts

Finding Cures Together: Donate Today

About This Blog
Contact Us
Blog Policies
Tips for Contributors
AACR.org